• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    OKYO Pharma Announces SAB Meeting & Urcosimod Data at ASCRS

    GLOBENEWSWIRE

    OKYO Pharma Shows Urcosimod Enhances Quality Of Life

    GLOBENEWSWIRE

    OKYO Abstract Chosen For Premier Global Ophthalmology Conference

    GLOBENEWSWIRE

    OKYO Pharma Presents Urcosimod Phase 2 Data at ASCRS Meeting

    GLOBENEWSWIRE

    OKYO Pharma To Ring The Opening Bell At Nasdaq

    GLOBENEWSWIRE

    Okyo`s Eye Drops Alleviate Neuropathic Pain in Phase 2 Success

    FIERCE BIOTECH

    OKYO Pharma`s Phase 2 Results for Urcosimod in Corneal Pain

    GLOBENEWSWIRE

    FDA Grants OKYO Fast Track for Urcosimod Neuropathic Corneal Pain

    GLOBENEWSWIRE

    OKYO Pharma Seeks FDA Fast Track for Urcosimod Neuropathic Cornea

    GLOBENEWSWIRE

    OKYO Pharma Announces OK-101 Phase 2 Clinical Trial Data For Dry Eye Disease

    PRESS RELEASE

    OKYO Pharma Announces Positive OK-101 Phase 2 Dry Eye Disease Data

    GLOBENEWSWIRE

    OKYO Pharma to Present OK-101 Ph2 Dry Eye Data at ARVO

    GLOBENEWSWIRE

    OKYO Pharma Announces Presentation of OK-101 Ph 2 Data for Dry Eye Disease

    GLOBENEWSWIRE

    OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

    GLOBENEWSWIRE

    OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance

    GLOBENEWSWIRE

    OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco

    GLOBENEWSWIRE

    OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial

    GLOBENEWSWIRE

    OKYO Pharma Announces Filing of an IND Application for OK-101

    GLOBENEWSWIRE

    OKYO Pharma Announces Data Profile for OK-101 Phase 2 Clinical Trial

    GLOBENEWSWIRE

    OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101

    GLOBENEWSWIRE

    OKYO Pharma Achieves 90% Enrollment in 240-Patient Ph2 Trial of OK-101

    GLOBENEWSWIRE

    OKYO Pharma Plans to Initiate PII of OK-101 in Neuropathic Corneal Pain

    GLOBENEWSWIRE

    OKYO Pharma Announces Phase 2 Clinical Trial of Topical Ocular OK-101

    GLOBENEWSWIRE

    OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial OK-101

    BIOSPACE

    OKYO Announces PII Trial of OK-101 Drug is listed on ClinicalTrials.gov Website

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.